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ABSTRACT
Objective:The objectives ofthis studywere to ascertain the acceptance rate ofhuman immunodeficie-
ncy virus type 1 (HIV-1) testing in a high-prevalence area and to describe the sociodemographic
and clinical characteristics of seropositive women diagnosed in the prenatal setting.
Methods: A retrospective review was carried out of the prenatal HIV-1 counseling and testing
program at University Hospital, Newark, NJ (1989-1990).
Results: Sixty-seven percent (741/1,114) ofthewomen offered HIV-1 counseling services accepted
testing and 40 (40/741:5.3%) new cases were identified. Heterosexual contact was the primary
exposure (17:52%) of these women, ofwhom 13 (73%) had negative syphilis serologies. Sixty-four
percent were asymptomatic. The mean absolute CD4 lymphocyte count in seropositive women
was 514 305 cells/mm3. Severe immunosuppression was seen in 7/32 (22%) patients. Seventy-
three percent (24/33) depended on public-assistance programs for their health-care services.
Conclusions: A voluntary HIV-1 counseling and testing program is well accepted in the prenatal
setting. It can provide early identification of asymptomatic seropositive women and infants at risk
and lead to early intervention and therapy. (C) 1996 Wiley-Liss, Inc.
KEY WORDS
HIV-1 seroprevalence, pregnancy, immunosuppression, AIDS
n the United States, the human immunodefi-
ciency virus (HIV)/acquired immunodeficiency
syndrome (AIDS) epidemic has increasingly af-
fected women of childbearing age from racial or
ethnic minorities living in urban communities. 1-3
HIV/AIDS is a leading cause of mortality for these
women. A delay in diagnosis and treatment fre-
quently results in increased morbidity from oppor-
tunistic infections such as PneumocTstis carinii pneu-
monia (PCP).S’6
The number of women with AIDS as well as
the HIV seroprevalence among parturients in New
Jersey is higher than the national average. 7’8 In gen-
eral, more than 80% of the women in the United
States seek the health-care system for reproductive
decisions including evaluation for sexually transmit-
ted diseases (STDs), family planning, and preg-
nancy. For example, in 1986, approximately 60%
of black and hispanic women and 75-80% of white
women initiated their prenatal care during the first
trimester of pregnancy. Therefore, the availability
of HIV-1 counseling and testing programs in these
settings could identify and educate women at risk.
In addition, these programs could provide the unin-
fected woman with knowledge of the modes ofHIV
transmission, identify risk behavior that may lead
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to the acquisition of HIV, and give the option of
selecting modalities effective in preventing preg-
nancy and STDs, including HIV. For the pregnant
woman, the early identification of HIV infection
provides an opportunity to 1) increase her knowl-
edge of the efficacy and toxicity of current treat-
ment methods; 2) make choices regarding her preg-
nancy1’11 and the obstetrical care that minimizes
morbidity and mortality of HIV disease; lz,3 3) initi-
ate strategies to reduce perinatal HIV-1 transmis-
sion; .4’15 and 4) provide early HIV diagnosis and
treatment of her newborn. 16’17 The pregnant HIV-
infected woman could also benefit from participat-
ing in clinical trials evaluating the current therapeu-
tic regimens.
18
Most HIV-1 counseling and testing of women
occur at either reproductive-health clinics (family-
planning or prenatal clinics), STD clinics, or HIV
counseling sites. 19,2 Sweeney et al. 21 found the high-
est median rate (0.63%) for HIV-1 infection among
minority women receiving prenatal services in the
United States and Puerto Rico. The lowest median
rate (0.21%)21 was observed among white women
attending abortion/family-planning clinics. Women
constituted 24% of all newly identified HIV-1 cases
in STD clinics in Baltimore. 22 The majority of these
women were asymptomatic with absolute CD4 lym-
phocyte counts of >-200/mm and intravenous drug
use (IVDU) as their primary exposure risk cate-
gory. 22 Prior studies have not explored the effect
of establishing HIV counseling and testing pro-
grams in prenatal clinics of HIV-1 prevalence areas
of >3/1,000 live births.
The goals of this study were to describe 1) the
acceptance rate of HIV-1 testing among women
attending a prenatal clinic in a high-prevalence area
during the first year of a counseling and testing
program, 2) the HIV-1 prevalence among pregnant
women attending a public prenatal clinic, and 3)
the sociodemographic and clinical characteristics of
these newly diagnosed women.
SUBJECTS AND METHODS
Routine, voluntary HIV-1 counseling and testing
were initiated in the prenatal clinic at University
Hospital, Newark, NJ, in September 1989. During
the first year (September 1989-August 1990) of this
program, any pregnant woman willing to accept an
individual, private counseling session (which lasted
15-30 min) received HIV-1 counseling as part ofher
initial prenatal visit. All counseling sessions were
provided by HIV counselors certified by the New
Jersey Department of Health Program. During
these sessions, the counselors provided information
regarding risk behavior, reliability of the assay to
detect HIV antibody, interpretation of the results,
and availability of therapeutic options. At the end
of each counseling session, each woman was asked
to sign a consent form if she desired HIV testing.
A woman considered at high risk for HIV-1 infec-
tion was also offered participation in the prospective
Perinatal HIV-1 Transmission Study (PHS) during
the counseling session. The factors judged to consti-
tute high risk for HIV-1 infection included past or
current substance abuse, partner ofan HIV-infected
male, partner of a bisexual or an IVDU male, sex
worker, recipient of a blood transfusion before 1985,
or birth in a pattern II country. An informed consent
approved by the Institutional Human Research
Committee was signed by each volunteer who
elected to participate in the PHS. Each woman
enrolled in the PHS had a lymphocyte profile done
at her initial visit as part of her research evaluation.
The sociodemographic data including a risk assess-
ment were collected. IVDU was considered the
mode of exposure for those women with docu-
mented prior or current IVDU. Heterosexual trans-
mission was considered the mode of exposure for
those women whose partners were HIV infected or
whose partners belonged to a high risk category such
as IVDU. All samples were analyzed for HIV-1 in an
AIDS Clinical Trials Group (ACTG)-certified labo-
ratory or a state-certified laboratory. The test results
were given during the post-test counseling sessions.
Awoman found to be negative was advised to repeat
the HIV testing in 6 months, while a woman found
to be HIV infected was offered treatment. The HIV-
positive pregnant women were also referred to ap-
propriate medical and social services.
An HIV-1 enzyme-linked immunosorbent assay
(Abbott, Chicago, IL) was used for screening all
samples. Persistent positive samples were con-
firmed by Western blot tests (Dupont, Wilmington,
DE). The interpretation of these assays was based
on the criteria used by the Association of State
Public Health Laboratory Directors/Centers for
Disease Control and Prevention (CDC). A lympho-
cyte subset analysis was done within 6 h of collec-
tion, using standard whole-blood lysing methodol-
ogy in an ACTG-certified laboratory.2
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The HIV-1 positive patients were assigned to
clinical categories (asymptomatic, symptomatic, or
AIDS) based on the CDC 1987 revised classification
system for HIV infection and disease in adolescents
and adults, z4 The patients with constitutional symp-
toms including fever (38.5C) or diarrhea lasting >
month, herpes zoster, pelvic inflammatory disease,
thrombocytopenia, or oropharyngeal candidiasis
(thrush) were categorized as symptomatic. The pa-
tients with HIV encephalopathy, malignancy, or op-
portunistic infections such as PCP, cytomegalovirus
disease, or candidiasis of the esophagus were classi-
fied as having AIDS. The patients were also classi-
fied using the 1993 expanded AIDS surveillance
case definition. This revised system expanded the
clinical AIDS category to include invasive cervical
cancer, recurrent pneumonia, and Mycobacterium tu-
berculosis infections. In addition, this system catego-
rized patients according to their immune compe-
tence within 3 CD4 lymphocyte count strata,
namely >-500, 200-499, and <200 cells/ll. Asymp-
tomatic or symptomatic patients with CD4 lympho-
cyte counts of <200 cells/ll met the immunologic
criteria for the diagnosis of AIDS. z5
The information regarding the number of new
patients attending the ambulatory clinic was ob-
tained from the annual OB/GYN departmental re-
port. The number of patients receiving HIV coun-
seling and screening was documented by the HIV
counselors assigned to the prenatal clinic during the
study period. The patient information was collected
using a standardized data collection form for all
participants of the PHS. In addition, health-care
resources and risk factors were included. The means
and standard deviations were calculated and used
to describe the sociodemographic and laboratory
parameters of the cohort.
RESULTS
Between September 1989 and August 1990, 1,114/
1,863 (60%) pregnantwomen attending the ambula-
tory low-risk prenatal clinic received HIV counsel-
ing. Of these, 741 (67%) women accepted HIV test-
ing during the study period. A trend toward an
increased acceptance rate for HIV testing over time
was noted, with a rise from 53% during the first 3
months to 73% between April and September 1990
(P 0.009) (Fig. 1). Forty new cases of HIV infec-
tion were identified (5.3% among women who
agreed to be tested). All of these patients were
residents of the inner city of Newark and sur-
rounding communities. Thirty-three (83%) HIV-
positive pregnant women consented to be followed
in the PHS, 3 patients did not receive their serosta-
tus until the postpartum visit, 2 refused HIV-related
care, and 2 were lost to follow-up in the prenatal
clinic.
Ninety-four percent of the newly identified HIV
positive pregnant women belonged to racial or eth-
nic minority groups. This distribution is representa-
tive of the population seen in the prenatal clinic
during the study period. The mean age of the sero-
positive women was 30 6 years, while 10 women
were 35 years or older (Fig. 2). The mean gestational
age at the time of diagnosis was 26 weeks (median
24 weeks); however, 8 patients received their diag-
nosis at <20 but >14 weeks gestation. No patient
was screened or tested at < 14 weeks. Of those who
received their diagnoses <20 weeks, none desired
an abortion. Two patients (>-35 years old) received
genetic counseling and amniocentesis prior to
knowledge of their serostatus. Heterosexual trans-
mission was the primary risk category (52%) and
IVDU the next highest (48%) Nine (9/33:27%)
pregnant women also tested positive for syphilis.
Five of these women had IVDU as their exposure
risk factor. The selected clinical characteristics of
the newly identified cases who received care
(N 33) are listed in Table 1.
The lymphocyte profile at the time of diagnosis
was available for 97% (32/33) ofthe women enrolled
in the PHS (Table 2). The clinical HIV-disease
stage was assigned at entry and reevaluated 6
months postpartum. No patient was found to have
clinical HIV-disease progression. However, when
comparing disease stages in this cohort based on
the 1987 adult/adolescent CDC classification with
the most recent 1993 definition, we found that 22%
(7/32) of the previously asymptomatic women met
the AIDS definition based on abnormal immune
profiles (Fig. 3). z3 The AIDS-defining illnesses seen
among the women in this cohort were PCP, AIDS
dementia, wasting syndrome, and oroesophageal
candidiasis. Overall, 6 patients in this cohort re-
ceived HIV-related medications during the antepar-
tum period for maternal indications. The drugs used
included antiretrovirals (N 3), PCP prophylaxis
(N 5), and antituberculosis medications (N 1).
Seventy-three percent (24/33) of the women re-
lied on public-assistance programs for their health
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Fig. I. Trend in acceptance rate (%) of HIV-I testing and HIV-I seroprevalence in the prenatal
clinic of University Hospital, Newark NJ (September 1989-August 1990).
Fig. 2. Age distribution of newly identified cases of HIV-I infection in pregnant women, University
Hospital, Newark, NJ (September 1989-August 1990).
care, 15% (5/33) were covered through their em-
ployer or their spouse’s employer, and 12% (4/33)
had no health-care resources. The most common
public-assistance programs used by this population
were Welfare, Aid for Families With Dependent
Children, and Supplemental Security Income. The
mean yearly income for women in the self-pay cate-
gory (not on public assistance) was $9,156.
DISCUSSION
The present study shows that 40 new cases of HIV
infection were identified during the first year of
establishing a counseling and testing program based
in the prenatal setting. The HIV-1 incidence seen
among childbearing women attending this prenatal
clinic was 5.3%. This observation supports the es-
tablishment of HIV-1 counseling and testing as a
routine component of prenatal care for women liv-
ing in areas of high prevalence. The increased ac-
ceptance of HIV-1 testing over the first year of this
program from 53 to 73% (P 0.04) suggests that
the prenatal clinic is an optimal setting to reach
childbearing-age women. For those women diag-
nosed as HIV infected, we incorporated their HIV-
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TABLE I. Selective clinical characteristics of newly
identified HIV-positive pregnant women
Characteristic N
Gestational age at time of diagnosis (N 33)
Ist trimester (<14 weeks) 0
2nd trimester (14-27 weeks) 19
3rd trimester (->28 weeks) 14
Baseline CD4 cells/txl (N 32)
->500 17
201-499 8
<200 7
Syphilis serology (N 32)
Positive 9
Negative 23
aDiagnosed as AIDS in the 1993 CDC expanded surveillance case defi-
nition.
related care in the prenatal setting, decreasing the
number of referral visits and availing their infants
of early HIV-1 diagnosis and treatment. We believe
that these factors, together with the increased expe-
rience gained by the counselors in improving pa-
tients’knowledge regarding the modes of exposure,
prolonged the survival of HIV-infected subjects.
We further believe that the availability of HIV-
related therapies and appropriate care was responsi-
ble for the increased acceptability of the program
among patients and health-care workers. Similar
programs should be available for women receiving
care in a private setting.
Most seropositive women in this study were
asymptomatic. In contrast to a report by Hutchinson
et al., zz the majority (73%) of the pregnant women
were negative for syphilis and were not IVDU.
These cases would have generally been missed us-
ing a risk-assessment approach alone. Of the clini-
cally asymptomatic women, 47% (15/32) had CD4
lymphocyte Counts that met the criteria for the initi-
ation of antiretroviral treatment at the time of diag-
nosis, lz Furthermore, 22% (7/32) of the women met
the criteria for the initiation of PCP prophylaxis.
13
The immunologic compromise of these pregnant
women was confirmed by the increase in the num-
ber of AIDS cases in the cohort when the 1993
adult/adolescent CDC definition was used (Figure
3). This expanded definition classifies individuals
with CD4 lymphocyte counts of <200 cells/mm in
the AIDS category (A3) surveillance,z The in-
creased survival observed among subjects on anti-
retroviral therapy and PCP prophylaxis and the
availability of such drugs through a state-supported
program warrant access to HIV testing during preg-
nancy and postpartum for women of reproductive
age.
Women are likely to access the health-care sys-
tem during pregnancy. Thus, broader availability of
HIV counseling and testing services in the prenatal-
care setting could identify new cases early in the
disease process. 18-zz Efforts to improve access to
early prenatal care for under-represented minorities
are essential to the success of any HIV counseling
and testing program. Ultimately, the long-term suc-
cess of these programs would require appropriate
referrals of HIV-infected women and their infants
to local or regional specialized-care networks.
The timely initiation of antiretroviral therapy or
PCP prophylaxis can delay the risk of disease pro-
gression or prevent the occurrence of common op-
portunistic infections in immunocompromised
pregnant women.’z’3 An avoidance of invasive pro-
cedures such as amniocentesis, chorionic villi sam-
pling, and fetal blood sampling has been recom-
mended to minimize perinatal transmission, z6 A
decrease in the length of ruptured membranes may
influence the risk ofperinatal transmission, z7 Conse-
quently, the identification of the HIV-infection sta-
tus in pregnant patients is critical to guide optimal
obstetrical practices. A knowledge of the HIV-1
infection status could also benefit the unborn child
by allowing the pregnant woman to exercise her
option of medical strategies that reduce perinatal
HIV transmission, such as the zidovudine regimen
used among the participants ofACTG 076. 3’14 The
neonates at risk of perinatal HIV infection can also
benefit from access to early diagnosis, prophylaxis,
and HIV-related therapy, if indicated. 16’7 Lastly,
some HIV-infected pregnant women may choose
to participate in clinical trials aimed at developing
safe and efficacious therapies in pregnancy and re-
ducing perinatal HIV transmission. 14’s
In our study, we observed a small discrepancy
between the HIV-1 seroprevalence in this prenatal
clinic (5.3%) and the results of the blinded analysis
of cord blood in 1987 (4.3%).z8 During the study
period, 40% (749/1,863) of the women did not re-
ceive HIV counseling, and 33% (373/1,114) refused
HIV testing. Consequently, the observed discrep-
ancy could be explained by a lower seroprevalence
rate among the patients who were not tested. Moni-
toring trends of HIV-testing acceptance and HIV
seroprevalence over time will be important to clarify
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TABLE 2. Lymphocyte profile at the time of diagnosis in pregnant HIV-positive women (N 32)
Immune marker (cells/ixl)
CD4 absolute CD4% CD8 absolute CD8% CD4/CD8
Mean +_ SD 514 _+ 305 29 13 937 402 56 12 0.57 0.30
Median 535 31 881 53 0.57
Fig. 3. HIV- -disease stage ofnewly identified cases of HIV- infection in pregnantwomen according
to 1987 and 1993 CDC adult/adolescent definition. Asym asymptomatic; Sym symptomatic.
this issue. Another limitation of our study was that
we did not ascertain factors associated with the ac-
ceptance of HIV testing during pregnancy. Ethnic
or cultural attitudes and beliefs influence the ac-
ceptability of HIV testing and HIV-related care. A
consideration of these factors might be relevant to
achieve the same degree of success when imple-
menting counseling and testing programs in other
communities. The benefits gained by the HIV-
infected individual and the institution that imple-
ments a prenatal HIV counseling and testing pro-
gram are influenced by the health-care attitudes
and beliefs of the members of that community.
Therefore, we cannot predict the success of this
approach in all communities.
In summary, the knowledge of one’s HIV status
offers many advantages to the mother and her in-
fant:5’12-18 an opportunity for education regarding
therapy for the mother-infant pair; the option to
initiate HIV-related therapy if indicated; the oppor-
tunity to discuss potential modifications in antepar-
turn and intrapartum care; the advantage of knowl-
edge regarding the serostatus of her neonate early
in the disease process; and the option for elective
termination of pregnancy. Although a knowledge
of one’s HIV status may have a negative impact
such as depression, suicide, or risk of battering,
the availability of multidisciplinary care and a sup-
port infrastructure can palliate the adverse conse-
quences for the mother-infant pair. Our study sug-
gests that routine HIV testing and counseling can be
implemented during the prenatal period for women
living in areas of high HIV-1 prevalence (>3 cases/
1,000 live births). We also described the therapeutic
benefit of this approach for the mother and fetus,
providing a rationale for implementation ofthe poli-
cies currently recommended by the New Jersey
Department of Health, American College of Obste-
tricians and Gynecologists, and CDC.
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